Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (91-100 of 296) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugatesSerengulam V Govindan, Thomas M Cardillo, Sung-Ju Moon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012
Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.
Arthritis Research & Therapy|April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusThomas Dörner, Joerg Kaufmann, William A Wegener, et al.
Molecular Cancer Therapeutics|July 24, 2014
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.
Mabs|February 5, 2014
A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electronsRosana B Michel, Adriane V Rosario, Philip M Andrews, et al.
Cancer Research|November 19, 2004
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancerDavid E Modrak, Thomas M Cardillo, Guy A Newsome, et al.
Nuclear Medicine and Biology|April 12, 2005
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivoRosana B Michel, Philip M Andrews, Adriane V Rosario, et al.
Pageof 30

Showing results (91-100 of 296) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugatesSerengulam V Govindan, Thomas M Cardillo, Sung-Ju Moon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphomaGary L Griffiths, Serengulam V Govindan, Robert M Sharkey, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012
Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.
Arthritis Research & Therapy|April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusThomas Dörner, Joerg Kaufmann, William A Wegener, et al.
Molecular Cancer Therapeutics|July 24, 2014
Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.
Mabs|February 5, 2014
A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.
Oncotarget|March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electronsRosana B Michel, Adriane V Rosario, Philip M Andrews, et al.
Cancer Research|November 19, 2004
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancerDavid E Modrak, Thomas M Cardillo, Guy A Newsome, et al.
Nuclear Medicine and Biology|April 12, 2005
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivoRosana B Michel, Philip M Andrews, Adriane V Rosario, et al.
Pageof 30